Background. -In-stent restenosis remains the major limitation of percutaneous coronary intervention (PCI), particularly after bare-metal stent (BMS) implantation. Drug-eluting stents (DES) decrease in-stent restenosis, which is thought to have minimal clinical consequences, but may increase the risk of stent thrombosis and its attendant high mortality rate. Risk-adjusted outcomes were calculated using propensity-score matching.
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Background
Since the first clinical angioplasty by Gruntzig in 1977 [1] and despite improved procedural equipment and pharmacotherapy [2] , restenosis has been the primary drawback of PCI [3] . The introduction of stents [4] proved to be a significant advance in reducing the frequency of restenosis, by retarding elastic recoil and negative remodelling at the treatment site [5] . Stents, however, failed to reduce neointimal hyperplasia [6] . The next advance, the DES, was designed to retard or eliminate this vascular response to injury. The use of the DES has led to a further substantial reduction in restenosis, but not to its elimination [7] [8] [9] [10] . A further concern has been raised: data suggest that DES deployment is complicated by stent thrombosis, more often than is the case with BMS deployment [11] . Some have argued that ISR after BMS deployment is a relatively benign process characterized by the recurrence of anginal symptoms, thereby offering little immediate threat to patients. In contrast, the more frequently occurring stent thrombosis, with its often-catastrophic consequences following DES deployment, may detract from the advantage conferred by the reduced rate of restenosis [12, 13] . No firm conclusion can be reached, since more recent studies suggest that BMS ISR may not be as benign as once thought and can result in an acute coronary syndrome [14, 15] . In fact, because of the infrequency of ISR following DES deployment, little is known about its clinical characteristics.
This study was designed with two goals in mind. First, we sought to reevaluate whether or not ISR is a significant concern after PCI. Next, we sought to compare the clinical syndrome produced by ISR following DES deployment with that produced after BMS use and to compare the outcomes of PCI in patients with BMS ISR and DES ISR.
Patients and methods
Data collection and study population
The data were extracted from our catheterization laboratory registry in compliance with the provisions of the Health Insurance and Portability Act of 1996 under a waiver granted by the MedStar Research Institute's institutional review board. All patients with DES ISR treated with PCI between April 2003 and September 2006 were compared with all patients with BMS ISR treated between January 1999 and April 2003. Both paclitaxel-coated DES (Taxus, Boston Scientific Corp., Natick, MA, USA) and sirolimuscoated DES (Cypher, Johnson and Johnson Cordis Corp., Warren, NJ, USA) were included. Patients presenting with stent thrombosis at the index angiogram were excluded. These data were obtained from hospital chart review by independent research personnel blinded to the study objectives. All data management, analysis and follow-up were performed by a dedicated data-coordinating centre (Data Center, Cardiovascular Research Institute, Washington, DC, USA).
Definitions
ISR was defined as greater than 50% luminal diameter stenosis by coronary angiography located within a previously stented arterial segment or within 5 mm proximal or distal to the stent, as identified from an angiogram performed after the index procedure. Angiographic success was defined as a thrombolysis in myocardial infarction grade 3 flow postprocedure, with a residual stenosis less than 30%. Unstable angina was defined as new-onset chest pain at rest or increase in severity of previously stable angina (an increase of ≥ 1 grade in Canadian Cardiovascular Society score).
Q-wave and non-Q-wave MI were defined as a total creatinine kinase elevation greater or equals to 3 times upper limit of vulnerability and/or CK-MB greater or equals to 2 timesupper limit of vulnerability plus new pathological Q-waves in at least two contiguous leads. TVR was defined as repeat percutaneous or surgical revascularization of the treated vessel. All were clinically driven. MACE were defined as all-cause mortality, Q-wave MI or TVR. Stent thrombosis was defined as angiographic evidence of thrombus in the target lesion less or equals to 360 days from the index treatment of the ISR.
Interventional strategies and adjunctive medical therapy
PCI was performed using conventional techniques. Differences in the treatment strategy between the patient groups were evident following the evolution of the material and of the guidelines. Finally, the interventional strategy regarding the ISR lesion was left entirely to the discretion of the operator. Revascularization of another narrowed segment of the target vessel or another vessel during the same procedure was performed as required.
All patients were treated with aspirin 325 mg before PCI and loaded with clopidogrel 300 to 600 mg if not already on a maintenance dose. During PCI, patients received either bivalirudin (a bolus of 0.75 mg/kg, followed by an intravenous infusion of 1.75 mg/kg/h) or unfractionated heparin (a bolus of 40 U/kg and additional heparin to achieve an activated clotting time of 250 to 300 s). Use of adjunctive devices and platelet glycoprotein IIb/IIIa inhibitors was at the discretion of the operator. After PCI, dual antiplatelet therapy was recommended for four weeks in those receiving BMS and for greater or equals to six months in those treated with DES. Clinical follow-up was conducted by telephone contact or office visit at 1 year. All events were confirmed with source documentation. Only the index artery was considered in calculating TVR.
Statistics
Comparisons of clinical, procedural and outcome variables for DES and BMS patients are presented. Continuous variables are reported as mean ± S.D. and compared using the Student's t test. Categorical variables are expressed as percentages and compared by means of contingency tables. Differences were tested with either the chi-square or the Fisher's exact test. A p value less than 0.05 was considered to indicate statistical significance. Statistical analysis was performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
Because of the variations in the baseline characteristics of the two cohorts, we performed a risk adjustment calculation by means of propensity-score matching. The propensity score was estimated from a non-parsimonious logistic regression model. The following variables were entered into the model: cardiovascular risk factors (male, age, diabetes, hypertension, hypercholesterolaemia, current smoking, body mass index), medical history (prior MI, prior coronary artery bypass, prior chronic heart failure, prior chronic renal insufficiency, prior peripheral vascular disease), clinical presentation (stable angina, unstable angina, acute MI), and angiographic data (left anterior descending, saphenous vein graft lesion). No interactions were considered in this model. The median propensity score in the DES ISR group was 0.124 (interquartile range: 0.081-0.197) and in the BMS ISR group was 0.073 (interquartile range: 0.025-0.116). One patient with DES ISR was then matched with two BMS ISR patients based on their propensity score using the nearest available pair matching method, by personnel blinded to patient outcomes. Quintiles were well matched for important variables, particularly those established to be predictive of stent thrombosis. The Hosmer and Lemeshow goodness-of-fit test was used to assess the model to fit to the data. The Chi-square test statistic was 10.3 (p = 0.24), which indicates a good fit of the model to the data. The c-statistic for the model was 0.729, indicating good discrimination.
Results
Baseline characteristics and clinical presentation
Between January 2000 and September 2006, a total of 2148 patients were admitted for treatment of ISR. One thousand nine hundred and fifty-eight patients had PCI of BMS ISR and 190 had PCI of DES ISR. Complete follow-up data for major clinical events were obtained in 90% of the overall cohort.
Baseline clinical characteristics are listed in Table 1 , Plot A. Numerous differences were present. Patients with DES ISR were more often female, more often reported hypertension, diabetes, hypercholesterolaemia and prior chronic heart failure, their body mass index was greater and they more often had serum creatinine greater or equals to 2.0 mg/L or were being treated for kidney disease.
In the overall population, 78.1% presented with unstable angina, 1.8% with acute MI and 20.1% with stable angina. Compared with patients with BMS ISR, patients with DES ISR presented more frequently with MI (4.3% versus 1.6%, p < 0.001) and stable angina pectoris (30.9% versus 19.1%, p < 0.001) (Fig. 1 ). Table 2 compares the angiographic and procedural features for patients with DES and BMS ISR. Saphenous vein grafts were less often the target for treatment of DES ISR and the degree of luminal narrowing was slightly less in that cohort. Differences in treatment strategy between the patient groups are clear. Patients with BMS ISR were more frequently restented, most often with another BMS. In patients with DES ISR who were restented, a second DES was most often deployed. The use of a cutting balloon and of a rotablator declined between the time frames of the two cohorts, resulting in less frequent use of the devices in DES ISR patients. Brachytherapy use was also less frequent in these patients. The use of IIb/IIIa platelet inhibitors was more frequent in the BMS ISR group (9.5% versus 4.3%, p = 0.01). Despite these differences in treatment strategies, the angiographic success was very high in both groups.
Angiographic and procedural characteristics
Outcome Unadjusted outcome
Unadjusted outcome is presented in Table 3 , Plot A. During follow-up, 122 patients (5.7%) died. Fourteen patients (0.7%) had a Q-wave MI and 8 (0.4%) had an acute stent thrombosis. TVR was performed in 460 patients (21.5%). All major cardiac events (TVR-MACE) concerned 562 patients (26.3%).
In-hospital results between the two patient cohorts were not different and the all-cause mortality and Q-wave MI rates were similar up to 1 year. On the other hand, by 30 days, patients with DES ISR had experienced more TVR (5.3% versus 2.4%, p = 0.02), more MACE (7% versus 3.7%, p = 0.02) and more stent thrombosis (1.6% versus 0.2%, p = 0.01) than those in the BMS ISR cohort. Between 30 days and 1 year, only one additional stent thrombosis was encountered in each group. Thus, while the preponderance of stent thrombosis in the DES ISR cohort persisted through 1 year (2.1% versus 0.2%, p = 0.003), the two groups were otherwise similar with regard to late outcomes.
Adjusted outcomes
To adjust for differences in baseline characteristics and their potential impact on outcome, we developed an analysis of outcomes after propensity-score matching of the two cohorts on baseline characteristics (Table 3 , Plot B). Details of propensity-score matching are provided in the Section Patients and methods.
The long-term clinical outcomes for the two cohorts after matching for baseline were very similar (Table 1, Plot B). However, some differences in management of patients in relation to the evolution of material and guidelines remained ( Table 2 , Plot B). Therefore, for an identical level of cardiovascular risk, there were no differences to 1 year in adverse events, with the exception of more TVR (p = 0.03), more total MACE (p = 0.06) and more stent thrombosis (p = 0.03) in the DES ISR group.
Discussion
The main finding of this study is that regardless of the type of stent, patients with ISR presented most often with an acute coronary syndrome. Further, the outcome was not particularly safe, with high rates of mortality and TVR-MACE at 1 year. Patients who had a DES ISR had a higher cardiovascular risk than patients with BMS ISR. After correction of the clinical difference between the two groups using propensityscore matching, the outcome was not different between the two groups except for a trend towards more TVR in the DES ISR group.
Is ISR a significant clinical problem?
The question of how serious restenosis is post-PCI has been raised since the inception of the procedure. Some reports have suggested that ISR is not a life-threatening event and that it is addressed relatively easily with an additional PCI [16, 17] . Some authors even thought that one does not die from ISR, whereas one does from stent thrombosis. Thus, the putative increase in stent thrombosis attributable to DES [11] might not justify implantation of DES to avoid a problem without clinical significance. Our data suggest that the presenting clinical syndrome is usually that of an unstable coronary syndrome (Table 1 , Plot A and Fig. 1 ). Our data are consistent with those of Park et al. [18] who reported an unstable presentation in 42% of patients with ISR and acute MI in 20%. Furthermore, Chen et al. [14] found that in patients with BMS ISR, 9.5% presented with acute MI, 26.4% presented with unstable angina requiring hospitalization before angiography and only 64.1% presented with exertional angina. Taken together with our data, it is reasonable to conclude that an unstable presentation is typical of ISR, regardless of the type of stent, and that an unstable syndrome implies a greater potential for lethal or disabling consequences [15] .
Regarding the outcome at 1 year, our data show that the occurrence of adverse cardiac events is equally significant (26.3%) as is the mortality rate (5.7%). A 5.7% risk of death after PCI for ISR is higher than the rate reported currently after PCI in a general setting, which is around 2% [19] . In line with a recent study [15] , our results tend to prove that ISR can influence the outcome of patients, including mortality. This consideration may help to explain why there is no difference in mortality in large studies comparing DES and BMS. The risk of mortality and MI associated with ISR or its management could balance any risk imposed by the putative increase in stent thrombosis attributable to DES [20] .
Is BMS ISR different from DES ISR?
The clinical presentation of ISR after DES deployment differed from that encountered after BMS implantation (Table 1 , Plot A). Patients with ISR after DES had significantly more stable angina (30.9% versus 19.1%, p < 0.001) and more acute MI (4.3% versus 1.6%, p < 0.001) than those with BMS ISR. It is tempting to speculate that the higher rate of acute MI at presentation resulted from a more rapid progression of the restenosis, perhaps linked in some way to the presumed greater propensity of the DES for stent thrombosis. On the other hand, because there are fewer ISRs in DES-treated patients, the proportion of more rapidly progressing obstruction, the presumed pathogenesis of MI in ISR, becomes greater. Further, patients with DES ISR had a higher cardiovascular risk profile, more often with hypertension, hypercholesterolaemia, obesity or renal insufficiency at admission. All of these conditions could create a greater trigger for inflammation and thrombosis [21] .
Our data suggest that outcomes of PCI for ISR are very similar whether the ISR occurred in a BMS or a DES. Indeed, the risk-adjusted mortality and Q-wave MI rates were indistinguishable up to 1 year and there was a trend only for a greater MACE in the DES ISR group (Table 3 , Plot B). On the other hand, the TVR rate by 1 year was significantly greater in patients in whom a DES was deployed at the initial procedure (p < 0.05). Thus, as our results suggest (Table 3 , Plot B), it is possible that a patient who develops ISR despite placement of a DES has a greater risk of a stent thrombosis than a similar patient with BMS, which is already known for de novo lesions. However, patients with DES ISR were treated less frequently with IIb/IIIa inhibitors -a treatment that could improve the outcome in ISR [22] .
Interventional strategies
In our registry, operators used somewhat different strategies for the management of ISR, according to the nature of the index stent ( Table 2 , Plot A). This relates, at least in part, to the fact that most BMS patients were treated before the release of the DES. With this in mind, it is clear that patients with BMS ISR were treated more often with an ablative device. This could reflect a more diffuse or proliferative pattern of ISR after BMS [23, 24] . After adjustment, management remained somewhat different between the two groups (Table 2, Plot B). Regardless of any differences in treatment strategies and apart from the possibility of a greater frequency of stent thrombosis when ISR followed DES implantation, the in-hospital and intermediate-term outcomes were similar.
Limitations
Our study is a retrospective analysis and is subject to the limitations inherent in this type of clinical investigation. The presentation of ISR as an unstable entity could have been overestimated due to the fact that the study population was composed of patients hospitalized for ISR. Patients with an asymptomatic or stable presentation who did not require hospitalization were therefore not considered. Despite the propensity matching of the population, there were some differences in the management of the two groups which could have affected the results.
Conclusions
The clinical presentation of ISR is most often an acute coronary syndrome. Although less life threatening than stent thrombosis, ISR is associated with greater morbidity and mortality than is expected currently in patients undergoing elective PCI. Furthermore, our data suggest that patients with ISR after DES implantation could have a greater risk of TVR than those whose initial stent was a BMS, possibly driven by more stent thrombosis.
